March 29, 2018 / 4:50 PM / 6 months ago

BRIEF-Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint

March 29 (Reuters) - Pfizer Inc:

* PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ATTR-ACT STUDY OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY

* PFIZER INC - STUDY MET ITS PRIMARY ENDPOINT

* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED

* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED IN POPULATION AND NO NEW SAFETY SIGNALS WERE IDENTIFIED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below